Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis

References

• Conneely SE, Stevens AM. 2021. Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy. Curr Oncol Rep. 23(2):16. doi:10.1007/s11912-020-01009-3.
   PubMed Web of Science ®Google Scholar
• Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J. 2020;103:38–9. 2013.
   Google Scholar
• Seth R, Singh A. 2015. Leukemias in children. Indian J Pediatr. 82(9):817–824. doi:10.1007/s12098-015-1695-5.
   PubMed Web of Science ®Google Scholar
• Kim H. 2020. Treatments for children and adolescents with AML. Blood Res. 55(S1):S5–13. doi:10.5045/br.2020.S002.
   PubMedGoogle Scholar
• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. 2016. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Boztug H, Mühlegger N, Glogova E, Mann G, Urban C, Meister B, Schmitt K, Jones N, Attarbaschi A, Haas O, et al. Development of treatment and clinical results in childhood AML in Austria (1993–2013). Memo. 2014;7(1):63–74. doi:10.1007/s12254-014-0135-y.
   PubMedGoogle Scholar
• Kiem Hao T, Van Ha C, Huu Son N, Nhu Hiep P. 2020. Long-term outcome of childhood acute myeloid leukemia: a 10-year retrospective cohort study. Pediatr Rep. 12(1):8486. doi:10.4081/pr.2020.8486.
   PubMed Web of Science ®Google Scholar
• Van Weelderen RE, Klein K, Natawidjaja MD, De Vries R, Kaspers GJ. 2021. Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. Expert Rev Anticancer Ther. 21(7):765–780. doi:10.1080/14737140.2021.1895756.
   PubMed Web of Science ®Google Scholar
• Davila J, Slotkin E, Renaud T. 2014. Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments. Paediatr Drugs. 16(2):151–168. doi:10.1007/s40272-013-0048-y.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell. 100(1):57–70. doi:10.1016/S0092-8674(00)81683-9.
   PubMed Web of Science ®Google Scholar
• Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol. 2010;2010:370835. doi:10.1155/2010/370835.
   PubMedGoogle Scholar
• Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. 1993. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81(11):3091–3096. doi:10.1182/blood.V81.11.3091.3091.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, et al. The anti-apoptotic genes Bcl-X L and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34 + cells. Br J Haematol. 2002;118(2):521–534. doi:10.1046/j.1365-2141.2002.03637.x.
   PubMed Web of Science ®Google Scholar
• Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dörken B, Ludwig WD. 2000. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol. 110(1):154–160. doi:10.1046/j.1365-2141.2000.02147.x.
   PubMed Web of Science ®Google Scholar
• Huyghe A, Furlan G, Ozmadenci D, Galonska C, Charlton J, Gaume X, Combémorel N, Riemenschneider C, Allègre N, Zhang J, et al. Netrin-1 promotes naive pluripotency through Neo1 and Unc5b co-regulation of Wnt and MAPK signalling. Nat Cell Biol. 2020;22(4):389–400. doi:10.1038/s41556-020-0483-2.
   PubMed Web of Science ®Google Scholar
• Kefeli U, Ucuncu Kefeli A, Cabuk D, Isik U, Sonkaya A, Acikgoz O, Ozden E, Uygun K. 2017. Netrin-1 in cancer: potential biomarker and therapeutic target? Tumour Biol J Int Soc Oncodevelopmental Biol Med. 39(4):1010428317698388. doi:10.1177/1010428317698388.
   Google Scholar
• Liu J, Yao F, Wu R, Morgan M, Thorburn A, Finley RL, Chen YQ. 2002. Mediation of the DCC apoptotic signal by DIP13α. J Biol Chem. 277(29):26281–26285. doi:10.1074/jbc.M204679200.
   PubMed Web of Science ®Google Scholar
• Llambi F, Causeret F, Bloch-Gallego E, Mehlen P. 2001. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. Embo J. 20(11):2715–2722. doi:10.1093/emboj/20.11.2715.
   PubMed Web of Science ®Google Scholar
• Dumartin L, Quemener C, Laklai H, Herbert J, Bicknell R, Bousquet C, Pyronnet S, Castronovo V, Schilling MK, Bikfalvi A, et al. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology. 2010;138 1595–606, 1606.e1-8(4). 10.1053/j.gastro.2009.12.061
   PubMed Web of Science ®Google Scholar
• Huang L, An X, Zhu Y, Zhang K, Xiao L, Yao X, Zeng X, Liang S, Yu J. 2022. Netrin-1 induces the anti-apoptotic and pro-survival effects of B-ALL cells through the Unc5b-MAPK axis. Cell Commun Signal CCS. 20(1):122. doi:10.1186/s12964-022-00935-y.
   PubMed Web of Science ®Google Scholar
• Hong K, Hinck L, Nishiyama M, Poo MM, Tessier-Lavigne M, Stein E. 1999. A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell. 97(7):927–941. doi:10.1016/S0092-8674(00)80804-1.
   PubMed Web of Science ®Google Scholar
• Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, Mehlen P. 2001. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci U S A. 98(6):3416–3421. doi:10.1073/pnas.051378298.
   PubMed Web of Science ®Google Scholar
• Hemmings BA. 1997. Akt signaling: linking membrane events to life and death decisions. Science. 275(5300):628–630. doi:10.1126/science.275.5300.628.
   PubMed Web of Science ®Google Scholar
• Xia X, Hu Z, Wang S, Yin K. Netrin-1: an emerging player in inflammatory diseases. Cytokine Growth Factor Rev. 2022;64:46–56. doi:10.1016/j.cytogfr.2022.01.003.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang S, Xu S, Han B. Netrin-1 protein expression in gastric cancer and its correlation with clinicopathologic features and prognosis. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011;42(6):802–806.
   PubMedGoogle Scholar
• Papanastasiou AD, Pampalakis G, Katsaros D, Sotiropoulou G. 2011. Netrin-1 overexpression is predictive of ovarian malignancies. Oncotarget. 2(5):363–367. doi:10.18632/oncotarget.258.
   PubMedGoogle Scholar
• Li L, Hu Y, Ylivinkka I, Li H, Chen P, Keski-Oja J, Hyytiäinen M, Zhang L. 2013. NETRIN-4 protects glioblastoma cells from temozolomide induced senescence. Plos One. 8(11):e80363. doi:10.1371/journal.pone.0080363.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Caca K, Eckstrand BC, Hu G, Lengauer C, Banavali S, Look AT, Fearon ER. 1999. Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas. Cell Growth Differ Mol Biol J Am Assoc Cancer Res. 10:35–42.
   Google Scholar
• Latil A, Chêne L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O. 2003. Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer. 103(3):306–315. doi:10.1002/ijc.10821.
   PubMed Web of Science ®Google Scholar
• X-Z A, Zhao Z-G, Luo Y-X, Zhang R, Tang X-Q, Hao D-L, Zhao X, Lv X, Liu D-P. 2016. Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer. Oncotarget. 7(17):24719–24733. doi:10.18632/oncotarget.8348.
   PubMedGoogle Scholar
• Bell CH, Healey E, van Erp S, Bishop B, Tang C, Gilbert RJC, Aricescu AR, Pasterkamp RJ, Siebold C. 2013. Structure of the repulsive guidance molecule (Rgm)–neogenin signaling hub. Science. 341(6141):77–80. doi:10.1126/science.1232322.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Deitinghoff L, Davis D, Conrad S, Skutella T, Chedotal A, Mueller BK, Strittmatter SM. 2004. Neogenin mediates the action of repulsive guidance molecule. Nat Cell Biol. 6(8):756–762. doi:10.1038/ncb1156.
   PubMed Web of Science ®Google Scholar
• Xu K, Wu Z, Renier N, Antipenko A, Tzvetkova-Robev D, Xu Y, Minchenko M, Nardi-Dei V, Rajashankar KR, Himanen J, et al. Neural migration. Structures of netrin-1 bound to two receptors provide insight into its axon guidance mechanism. Science. 2014;344(6189):1275–1279. doi:10.1126/science.1255149.
   PubMed Web of Science ®Google Scholar
• Lu X, Le Noble F, Yuan L, Jiang Q, De Lafarge B, Sugiyama D, Bréant C, Claes F, De Smet F, Thomas J-L, et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature. 2004;432(7014):179–186. doi:10.1038/nature03080.
   PubMed Web of Science ®Google Scholar
• Ko SY, Dass CR, Nurgali K. 2012. Netrin-1 in the developing enteric nervous system and colorectal cancer. Trends Mol Med. 18(9):544–554. doi:10.1016/j.molmed.2012.07.001.
   PubMed Web of Science ®Google Scholar
• Yin K, Wang L, Zhang X, He Z, Xia Y, Xu J, Wei S, Li B, Li Z, Sun G, et al. Netrin-1 promotes gastric cancer cell proliferation and invasion via the receptor neogenin through PI3K/AKT signaling pathway. Oncotarget. 2017;8(31):51177–51189. doi:10.18632/oncotarget.17750.
   PubMedGoogle Scholar
• Sabbatini P, McCormick F. 1999. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem. 274(34):24263–24269. doi:10.1074/jbc.274.34.24263.
   PubMed Web of Science ®Google Scholar
• Yamaguchi A, Tamatani M, Matsuzaki H, Namikawa K, Kiyama H, Vitek MP, Mitsuda N, Tohyama M. 2001. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J Biol Chem. 276(7):5256–5264. doi:10.1074/jbc.M008552200.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat Rev Cancer. 2(7):489–501. doi:10.1038/nrc839.
   PubMed Web of Science ®Google Scholar
• Sulzmaier FJ, Jean C, Schlaepfer DD. 2014. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 14(9):598–610. doi:10.1038/nrc3792.
   PubMed Web of Science ®Google Scholar
• Guo Z, Mo Z. 2020. Keap1-Nrf2 signaling pathway in angiogenesis and vascular diseases. J Tissue Eng Regen Med. 14(6):869–883. doi:10.1002/term.3053.
   PubMed Web of Science ®Google Scholar
• Herfindal L, Selheim F. 2006. Microcystin produces disparate effects on liver cells in a dose dependent manner. Mini Rev Med Chem. 6(3):279–285. doi:10.2174/138955706776073475.
   PubMed Web of Science ®Google Scholar
• Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–3205. doi:10.1182/blood-2012-03-362608.
   PubMed Web of Science ®Google Scholar